Sanofi-Aventis unifies its generics business in Europe under Zentiva brand name
This article was originally published in Scrip
Sanofi-Aventis has announced the unification of its generic drugs business in Europe under Zentiva brand name. Zentiva is the Czech Republic's largest manufacturer of generic pharmaceuticals that Sanofi-Aventis acquired in a cash deal in 2009 after intensive negotiations with its shareholders (scripintelligence.com, 12 March 2009).
You may also be interested in...
Poland's president, Bronislaw Komorowski, has signed a reimbursement bill into the law which will come into force on 1 January.
In the past two years, most multinational pharmaceutical companies announced plans to create production facilities in Russia. They had been ignoring such an opportunity for years, and there were reasons for that. They included risks to investments, administrative barriers, unclear regulations assuming various interpretations and corruption.
Russia's president Dmitriy Medvedev has requested that his government start talks with the US and the EU on the mutual recognition of clinical trial results (including paediatric trials) and prepare proposals for corresponding amendments of existing regulations.